Medizinische Hochschule Hannover

Investment thesis

The Medizinische Hochschule Hannover (MHH) exists to advance translational medicine and clinical research, bridging the gap between laboratory discovery and patient care through its integrated university hospital model. It funds work that directly impacts human health, with a strategic agenda focused on:

• Translational research: Accelerating the path from bench to bedside, particularly in oncology, immunology, and regenerative medicine.
• Rare diseases: Dedicated research into conditions with unmet clinical needs, supported by specialized centres and patient registries.
• Digital health and AI: Integrating artificial intelligence into early cancer detection, genetic risk communication, and clinical decision support.
• Health services research: Improving care delivery, workforce sustainability, and patient outcomes through systematic study.

Credibility: The MHH’s dual role as a university and maximum-care hospital in Hanover provides direct access to patient cohorts and clinical data, enabling real-world validation of research findings.

Value add

Beyond funding, the MHH provides access to a unique clinical environment, expert networks, and institutional support for translational work. Its integrated model allows researchers to test hypotheses in real-world settings, accelerating development.

Fit verdict: Ideal for teams seeking clinical validation, patient access, and interdisciplinary collaboration in translational medicine.

Founder diligence script:

• Does my project align with MHH’s translational focus areas?
• Can I leverage their clinical infrastructure and patient cohorts?
• What internal calls or partnerships are available for my stage?
• How does the MHPlus Foundation support early-stage innovation?
• What reporting and compliance requirements apply to awarded projects?

Portfolio focus

• Translational oncology projects with clinical trial components.
• Regenerative medicine and stem cell research with therapeutic potential.
• AI-driven tools for early cancer detection and risk assessment.
• Rare disease research, including genetic therapies and diagnostic innovations.
• Health services research focused on care delivery and workforce sustainability.